The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 3, double-blind, multicenter trial.
 
Xinan Sheng
No Relationships to Disclose
 
Dingwei Ye
No Relationships to Disclose
 
Ai-Ping Zhou
No Relationships to Disclose
 
Xin Yao
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Zhisong He
No Relationships to Disclose
 
Zengjun Wang
No Relationships to Disclose
 
Yingchao Zhao
No Relationships to Disclose
 
Zhigang Ji
No Relationships to Disclose
 
Qing Zou
No Relationships to Disclose
 
Chaohong He
No Relationships to Disclose
 
Jianming Guo
No Relationships to Disclose
 
Xinhua Tu
No Relationships to Disclose
 
Ziling Liu
No Relationships to Disclose
 
Benkang Shi
No Relationships to Disclose
 
Ben Liu
No Relationships to Disclose
 
Peng Chen
No Relationships to Disclose
 
Qiang Wei
No Relationships to Disclose
 
Fang-Jian Zhou
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere